Research Articles | Page 5 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Research Articles

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naive patients with PNH (COMMODORE 3): A multicenter, Phase 3, single-arm study Jul 2023 American Journal of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Alemtuzumab in relapsed immune severe aplastic anemia: Long-term results of a phase II study Jun 2023 American Journal of Hematology Aplastic Anemia
Alemtuzumab in relapsed immune severe aplastic anemia: Long-term results of a phase II study Apr 2023 American Journal of Hematology Aplastic Anemia
Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management" Jan 2021 American Journal of Hematology Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN)
Clinical decision-making and treatment of myelodysplastic syndromes Dec 2023 American Journal of Hematology Myelodysplastic Syndromes (MDS)
Massive hemolysis in paroxysmal nocturnal hemoglobinuria after switching from proximal complement inhibitor to anti-C5 therapy: A lesson not to be forgotten Oct 2024 American Journal of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes Jan 2021 American Journal of Hematology Myelodysplastic Syndromes (MDS)
Elderly Patients With Aplastic Anemia: Treatment Patterns and Outcomes in the Real World Apr 2025 American Journal of Hematology Aplastic Anemia
New Approvals in Low- and Intermediate-Risk Myelodysplastic Syndromes May 2025 American Society of Clinical Oncology Educational Book Myelodysplastic Syndromes (MDS)
Haploidentical stem cell transplantation (haplo-SCT) represents the main alternative for children with inherited bone marrow failure syndrome (I-BMF) lacking a matched donor. This retrospective study, conducted on behalf of the EBMT SAAWP and PDWP, aims t Jun 2024 American Society of Clinical Oncology Educational Book Myelodysplastic Syndromes (MDS)